Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are conducting a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INI-822, a drug being studied in healthy volunteers and participants with Metabolic Dysfunction-Associated Steatohepatitis MASH or presumed MASH. The study includes multiple parts involving different participant groups to assess various dosing regimens and formulations. The study is divided into six parts, enrolling approximately 168 participants total. Parts A, B, D, and F involve healthy volunteers receiving single or multiple ascending doses of INI-822 or placebo orally once daily. Parts C and E involve participants diagnosed with MASH or presumed MASH. Each part has distinct cohorts and durations ranging from 5 to 18 weeks, including screening. Some parts include crossover designs to assess food effects or tablet formulations. Participants will attend scheduled visits for screening, dosing, and follow-up assessments for up to 18 weeks depending on the study part. Researchers will monitor adverse events, clinical laboratory results, and pharmacokinetic parameters such as drug concentration over time. The study is randomized, double-blind, and placebo-controlled, with safety and laboratory abnormalities as primary outcomes. Participants will be closely observed throughout their assigned part of the trial.